TN2009000469A1 - Organic compounds - Google Patents

Organic compounds

Info

Publication number: TN2009000469A1
Authority: TN; Tunisia
Prior art keywords: organic compounds; conditions; blockade; tautomers; solvates
Prior art date: 2007-05-07

Application number

TNP2009000469A

Other languages

English (en)

Inventor

Robin Alec Fairhurst

Rebecca Butler

Paul Oakley

Stephen Paul Collingwood

Nichola Smith

Emily Stanley

Perez Maria Ines Rodriguez

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-05-07

Filing date

2009-11-06

Publication date

2011-03-31

2009-11-06 Application filed by Novartis Ag filed Critical Novartis Ag

2011-03-31 Publication of TN2009000469A1 publication Critical patent/TN2009000469A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

TNP2009000469A 2007-05-07 2009-11-06 Organic compounds TN2009000469A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP07107654		2007-05-07
PCT/EP2008/055497 WO2008135557A1 (fr)	2007-05-07	2008-05-05	Composés organiques

Publications (1)

Publication Number	Publication Date
TN2009000469A1 true TN2009000469A1 (en)	2011-03-31

Family

ID=38581916

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2009000469A TN2009000469A1 (en)	2007-05-07	2009-11-06	Organic compounds

Country Status (31)

Country	Link
US (1)	US8318935B2 (fr)
EP (2)	EP2332933A1 (fr)
JP (1)	JP5244904B2 (fr)
KR (1)	KR20100005730A (fr)
CN (1)	CN101687851B (fr)
AR (1)	AR066458A1 (fr)
AT (1)	ATE499363T1 (fr)
AU (1)	AU2008248598B2 (fr)
BR (1)	BRPI0811562A2 (fr)
CA (1)	CA2685546A1 (fr)
CL (1)	CL2008001301A1 (fr)
CO (1)	CO6290667A2 (fr)
CR (1)	CR11091A (fr)
DE (1)	DE602008005140D1 (fr)
EA (1)	EA200901489A1 (fr)
EC (1)	ECSP099718A (fr)
ES (1)	ES2361595T3 (fr)
GT (1)	GT200900289A (fr)
HN (1)	HN2009003214A (fr)
IL (1)	IL201828A0 (fr)
MA (1)	MA31400B1 (fr)
MX (1)	MX2009012077A (fr)
NZ (1)	NZ580737A (fr)
PE (1)	PE20090733A1 (fr)
PL (1)	PL2155721T3 (fr)
PT (1)	PT2155721E (fr)
SV (1)	SV2009003406A (fr)
TN (1)	TN2009000469A1 (fr)
TW (1)	TWI351402B (fr)
WO (1)	WO2008135557A1 (fr)
ZA (1)	ZA200907491B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6858615B2 (en)	2002-02-19	2005-02-22	Parion Sciences, Inc.	Phenyl guanidine sodium channel blockers
CA2713413C (fr)	2008-02-26	2018-11-20	Parion Sciences, Inc.	Bloqueurs poly-aromatiques de canaux sodiques
KR20110085768A (ko)	2010-01-21	2011-07-27	삼성전자주식회사	Ｃｍｏｓ 이미지 센서, 상기 이미지 센서의 데이터 리드아웃 방법, 및 상기 이미지 센서를 포함하는 전자 시스템
US8372845B2 (en) *	2010-09-17	2013-02-12	Novartis Ag	Pyrazine derivatives as enac blockers
US9050339B2 (en)	2010-09-17	2015-06-09	Novartis Ag	Pyrazine derivatives as ENaC blockers
AR086745A1 (es)	2011-06-27	2014-01-22	Parion Sciences Inc	3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
EP2773633B1 (fr)	2011-11-02	2017-08-02	Boehringer Ingelheim International GmbH	Composés hétérocycliques, médicaments contenant ces composés, utilisation associée et procédés de préparation correspondants
EP2773624A1 (fr)	2011-11-02	2014-09-10	Boehringer Ingelheim International GmbH	Nouveau procédé pour la préparation d'acylguanidines et d'acylthiourées
US8859559B2 (en) *	2011-12-20	2014-10-14	Boehringer Ingelheim International Gmbh	Substituted pyrazines and their use in the treatment of disease
US10774132B2 (en)	2012-01-09	2020-09-15	The Scripps Research Instittue	Ultralong complementarity determining regions and uses thereof
EP2861577B1 (fr)	2012-05-25	2017-01-04	Boehringer Ingelheim International GmbH	Amines tertiaires, médicaments contenant ces amines, utilisation associée et procédés de préparation correspondants
EP2897940B1 (fr) *	2012-09-24	2019-05-01	Boehringer Ingelheim International GmbH	Composés hétérocycliques, médicaments contenant ces composés, leur utilisation et procédés de leur préparation
SG11201503365YA (en)	2012-11-02	2015-06-29	Vertex Pharma	Pharmaceutical compositions for the treatment of cftr mediated diseases
SMT201700107T1 (it)	2012-12-17	2017-03-08	Parion Sciences Inc	Derivati di cloro-pirazina carbossammide utili per il trattamento di patologie favorite da idratazione insufficiente della mucosa
NZ709197A (en)	2012-12-17	2020-06-26	Parion Sciences Inc	3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
JP6353032B2 (ja) *	2013-04-30	2018-07-04	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ジアミノピラジン化合物、前記化合物を含有する医薬、その使用、およびその調製方法
AU2014284268A1 (en) *	2013-07-02	2016-01-07	The California Institute For Biomedical Research	Compounds for treatment of cystic fibrosis
US9102633B2 (en)	2013-12-13	2015-08-11	Parion Sciences, Inc.	Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
UY36034A (es)	2014-03-18	2015-09-30	Astrazeneca Ab	Derivados de 3,5-diamino-6-cloro-pirazina-2-carboxamida y sales farmaceuticamente aceptables de estos
CA2940599A1 (fr)	2014-03-27	2015-10-01	Novartis Ag	Dispersions d'huile-dans-l'eau solides sechees par pulverisation pour l'inhalation de principes pharmaceutiques actifs
GB201412545D0 (en) *	2014-07-15	2014-08-27	Univ Manchester The And Manchester Metropolitan University	Enzymatic processes and uses
CN107405505A (zh) *	2015-01-07	2017-11-28	加州生物医学研究所	用于治疗囊性纤维化的化合物
US9932324B2 (en) *	2015-01-12	2018-04-03	Boehringer Ingelheim International Gmbh	Substituted benzimidazolium compounds useful in the treatment of respiratory diseases
US10155749B2 (en) *	2015-01-12	2018-12-18	Boehringer Ingelheim International Gmbh	Substituted benzimidazolium compounds useful in the treatment of respiratory diseases
US20180002312A1 (en) *	2015-01-12	2018-01-04	Boehringer Ingelheim International Gmbh	Tetra- and pentasubstituted benzimidazolium compounds useful in the treatment of respiratory diseases
US10291868B2 (en) *	2016-01-29	2019-05-14	SK Hynix Inc.	Image sensing device
GB201610854D0 (en)	2016-06-21	2016-08-03	Entpr Therapeutics Ltd	Compounds
GB201619694D0 (en)	2016-11-22	2017-01-04	Entpr Therapeutics Ltd	Compounds
WO2018175340A1 (fr)	2017-03-20	2018-09-27	Sienna Biopharmaceuticals, Inc.	Conjugués d'exposition réduite modulant des cibles thérapeutiques
WO2018175302A1 (fr)	2017-03-20	2018-09-27	Sienna Biopharmaceuticals, Inc.	Conjugués polymères ciblant c-src à exposition réduite
GB201717051D0 (en)	2017-10-17	2017-11-29	Enterprise Therapeutics Ltd	Compounds
GB201808093D0 (en)	2018-05-18	2018-07-04	Enterprise Therapeutics Ltd	Compounds

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1219606A (en)	1968-07-15	1971-01-20	Rech S Et D Applic Scient Soge	Quinuclidinol derivatives and preparation thereof
US3544571A (en)	1968-09-04	1970-12-01	Merck & Co Inc	Process for making pyrazinoylthiourea compounds
US4246406A (en)	1979-03-27	1981-01-20	Merck & Co., Inc.	Heterocyclic substituted pyrazinoylguanidines
JPS6235216A (ja)	1985-08-09	1987-02-16	Noritoshi Nakabachi	不均質物質層の層厚非破壊測定方法および装置
GB8923590D0 (en)	1989-10-19	1989-12-06	Pfizer Ltd	Antimuscarinic bronchodilators
PT100441A (pt)	1991-05-02	1993-09-30	Smithkline Beecham Corp	Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
WO1993018007A1 (fr)	1992-03-13	1993-09-16	Tokyo Tanabe Company Limited	Nouveau derive de carbostyrile
WO1993019750A1 (fr)	1992-04-02	1993-10-14	Smithkline Beecham Corporation	Composes efficaces dans le traitement de maladies allergiques ou inflammatoires
AU3924993A (en)	1992-04-02	1993-11-08	Smithkline Beecham Corporation	Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor
FI944549L (fi)	1992-04-02	1994-11-30	Smithkline Beecham Corp	Allergisten ja tulehdussairauksien hoidossa käyttökelpoiset yhdisteet
TW394760B (en) *	1993-09-07	2000-06-21	Hoffmann La Roche	Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
GB9622386D0 (en)	1996-10-28	1997-01-08	Sandoz Ltd	Organic compounds
US6166037A (en)	1997-08-28	2000-12-26	Merck & Co., Inc.	Pyrrolidine and piperidine modulators of chemokine receptor activity
WO1999016766A1 (fr)	1997-10-01	1999-04-08	Kyowa Hakko Kogyo Co., Ltd.	Derives de benzodioxole
US6541669B1 (en)	1998-06-08	2003-04-01	Theravance, Inc.	β2-adrenergic receptor agonists
DE69827673T2 (de)	1998-06-30	2005-04-21	Dow Global Technologies Inc	Polymerpolyole und ein verfahren zu ihrer darstellung
GB9913083D0 (en)	1999-06-04	1999-08-04	Novartis Ag	Organic compounds
SK286641B6 (sk)	1999-05-04	2009-03-05	Schering Corporation	Piperazínové deriváty užitočné ako CCR5 antagonisty, farmaceutické prípravky s ich obsahom a ich použitie
CZ301161B6 (cs)	1999-05-04	2009-11-18	Schering Corporation	Piperidinopiperidylový derivát užitecný jako CCR5 antagonista, farmaceutický prostredek jej obsahující
ES2165768B1 (es)	1999-07-14	2003-04-01	Almirall Prodesfarma Sa	Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US6475509B1 (en) *	1999-07-19	2002-11-05	The University Of North Carolina At Chapel Hill	Covalent conjugates of sodium channel blockers and active compounds
TR200909479T2 (tr)	1999-08-21	2012-02-21	Nycomed Gmbh	Sinerjistik kombinasyon.
OA11558A (en)	1999-12-08	2004-06-03	Advanced Medicine Inc	Beta 2-adrenergic receptor agonists.
MXPA02010179A (es)	2000-04-27	2003-04-25	Boehringer Ingelheim Pharma	Nuevos betamimeticos de larga accion, procedimiento para su preparacion y su empleo como medicamentos.
BR0112297A (pt)	2000-06-27	2003-05-06	S A L V A T Lab Sa	Compostos carbamatos derivados de arilalquilaminas
GB0015876D0 (en)	2000-06-28	2000-08-23	Novartis Ag	Organic compounds
DE10038639A1 (de)	2000-07-28	2002-02-21	Schering Ag	Nichtsteroidale Entzündungshemmer
IL154175A0 (en)	2000-08-05	2003-07-31	Glaxo Group Ltd	17. beta.-carbothioate 17. alpha-arylcarbonyloxyloxy androstane derivatives as anti-inflammatory agents
GB0028383D0 (en)	2000-11-21	2001-01-03	Novartis Ag	Organic compounds
DE60113719T2 (de)	2000-12-22	2006-09-28	Almirall Prodesfarma Ag	Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
SK287414B6 (sk)	2000-12-28	2010-09-07	Laboratorios Almirall, S.A.	Chinuklidínové deriváty a kompozície s ich obsahom
GB0103630D0 (en)	2001-02-14	2001-03-28	Glaxo Group Ltd	Chemical compounds
DE60220887T2 (de)	2001-03-08	2008-02-28	Glaxo Group Ltd., Greenford	Agonisten von beta-adrenorezeptoren
DE60224172T2 (de)	2001-03-22	2008-12-04	Glaxo Group Ltd., Greenford	Formanilid-derivative als beta2-adrenorezeptor-agonisten
MXPA03009940A (es)	2001-04-30	2004-01-29	Glaxo Group Ltd	DERIVADOS ANTI-INFLAMATORIOS DE 17. BETA-CARBOTIOATO ESTER DE ANDROSTANO CON UN GRUPO DE ESTER CICLICO EN LA POSICIoN 17.ALFA.
US20040248867A1 (en)	2001-06-12	2004-12-09	Keith Biggadike	Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives
EP2319919B1 (fr)	2001-06-21	2015-08-12	BASF Enzymes LLC	Nitralases
PL393155A1 (pl)	2001-09-14	2011-03-28	Glaxo Group Limited	Pochodne fenetanoloaminy do leczenia chorób układu oddechowego
CA2462980A1 (fr)	2001-10-17	2003-04-24	Ucb, S.A.	Derives de quinuclidine, leurs procedes de preparation, et leurs utilisations en tant qu'inhibiteurs de recepteur muscarinique m2 et/ou m3
GB0125259D0 (en)	2001-10-20	2001-12-12	Glaxo Group Ltd	Novel compounds
AR037517A1 (es)	2001-11-05	2004-11-17	Novartis Ag	Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
TWI249515B (en)	2001-11-13	2006-02-21	Theravance Inc	Aryl aniline beta2 adrenergic receptor agonists
WO2003042160A1 (fr)	2001-11-13	2003-05-22	Theravance, Inc.	Agonistes de recepteur d'aryl aniline beta-2 adrenergique
AU2002356759A1 (en)	2001-12-01	2003-06-17	Glaxo Group Limited	17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
UA76571C2 (en)	2001-12-20	2006-08-15		Derivatives of 1-alkyl-1-azoniabicyclo [2.2.2.]octanecarbamate and use thereof as antagonists of muscarin receptor
AU2003202044A1 (en)	2002-01-15	2003-09-09	Glaxo Group Limited	17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
AU2003201693A1 (en)	2002-01-21	2003-09-02	Glaxo Group Limited	Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
GB0202216D0 (en)	2002-01-31	2002-03-20	Glaxo Group Ltd	Novel compounds
GB0204719D0 (en)	2002-02-28	2002-04-17	Glaxo Group Ltd	Medicinal compounds
EP1490317A1 (fr)	2002-03-26	2004-12-29	Boehringer Ingelheim Pharmaceuticals Inc.	Mimetiques du glucocorticoide, procedes de fabrication de ces mimetiques, compositions pharmaceutiques et leurs utilisations
MXPA04009329A (es)	2002-03-26	2005-01-25	Boehringer Ingelheim Pharma	Mimeticos de glucocorticoides, metodos para su preparacion, composiciones farmaceuticas y usos de los mismos.
JP4570878B2 (ja)	2002-04-11	2010-10-27	メルク・シャープ・エンド・ドーム・コーポレイション	選択的糖質コルチコイド受容体モジュレーターとしての１Ｈ−ベンゾ［ｆ］インダゾール−５−イル誘導体
ES2206021B1 (es)	2002-04-16	2005-08-01	Almirall Prodesfarma, S.A.	Nuevos derivados de pirrolidinio.
ES2298511T3 (es)	2002-04-25	2008-05-16	Glaxo Group Limited	Derivados de fenetanolamina.
US6747043B2 (en)	2002-05-28	2004-06-08	Theravance, Inc.	Alkoxy aryl β2 adrenergic receptor agonists
US7186864B2 (en)	2002-05-29	2007-03-06	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
ES2201907B1 (es)	2002-05-29	2005-06-01	Almirall Prodesfarma, S.A.	Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos.
DE10224888A1 (de)	2002-06-05	2003-12-24	Merck Patent Gmbh	Pyridazinderivate
US7074806B2 (en)	2002-06-06	2006-07-11	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10225574A1 (de)	2002-06-10	2003-12-18	Merck Patent Gmbh	Aryloxime
DE10227269A1 (de)	2002-06-19	2004-01-08	Merck Patent Gmbh	Thiazolderivate
WO2004000814A1 (fr)	2002-06-25	2003-12-31	Merck Frosst Canada & Co.	Inhibiteurs de pde4 8-(biaryle)quinolines
WO2004005258A1 (fr)	2002-07-02	2004-01-15	Merck Frosst Canada & Co.	Ethane pyridone a substitution diaryle, inhibiteurs d'enzyme pde4
ES2204295B1 (es)	2002-07-02	2005-08-01	Almirall Prodesfarma, S.A.	Nuevos derivados de quinuclidina-amida.
BR0312575A (pt)	2002-07-08	2005-05-03	Pfizer Prod Inc	Moduladores do receptor de glicocorticóides
GB0217225D0 (en)	2002-07-25	2002-09-04	Glaxo Group Ltd	Medicinal compounds
PE20050130A1 (es)	2002-08-09	2005-03-29	Novartis Ag	Compuestos organicos
CA2494634A1 (fr)	2002-08-10	2004-03-04	Altana Pharma Ag	Piperidine-pyridazones et phthalazones en tant qu'inhibiteurs de pde4
HRP20050197A2 (en)	2002-08-10	2006-06-30	Altana Pharma Ag	Piperidine-n-oxide-derivatives
WO2004018451A1 (fr)	2002-08-10	2004-03-04	Altana Pharma Ag	Derives de pyridazinone utilises comme inhibiteurs de pde4
AU2003255376A1 (en)	2002-08-10	2004-03-11	Altana Pharma Ag	Piperidine-derivatives as pde4 inhibitors
PL374014A1 (en)	2002-08-17	2005-09-19	Altana Pharma Ag	Novel phenanthridines having pde 3/4 inhibiting properties
HRP20050227A2 (en)	2002-08-17	2006-06-30	Altana Pharma Ag	Novel benzonaphthyridines
SE0202483D0 (sv)	2002-08-21	2002-08-21	Astrazeneca Ab	Chemical compounds
EP1532113B1 (fr)	2002-08-21	2008-08-06	Boehringer Ingelheim Pharmaceuticals Inc.	Composes mimetiques de glucocorticoide, leurs procedes de fabrication, compositions pharmaceutiques, et leurs utilisations
DE60231341D1 (de)	2002-08-23	2009-04-09	Ranbaxy Lab Ltd	Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
US7329676B2 (en)	2002-08-29	2008-02-12	Nycomed Gmbh	2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors
WO2004019935A1 (fr)	2002-08-29	2004-03-11	Boehringer Ingelheim Pharmaceuticals, Inc.	Derives de -3 (sulfonamidoethyl) -indole destines a etre utilises comme agents mimetiques glucocorticoides dans le traitement des maladies inflammatoires, allergiques et proliferatives
AU2003273805B8 (en)	2002-08-29	2010-06-17	Takeda Gmbh	3-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors
GB0220730D0 (en)	2002-09-06	2002-10-16	Glaxo Group Ltd	Medicinal compounds
JP2006096662A (ja)	2002-09-18	2006-04-13	Sumitomo Pharmaceut Co Ltd	新規６−置換ウラシル誘導体及びアレルギー性疾患の治療剤
JPWO2004026873A1 (ja)	2002-09-18	2006-01-19	小野薬品工業株式会社	トリアザスピロ［５．５］ウンデカン誘導体およびそれらを有効成分とする薬剤
JP2004107299A (ja)	2002-09-20	2004-04-08	Japan Energy Corp	新規１−置換ウラシル誘導体及びアレルギー性疾患の治療剤
CA2499150A1 (fr)	2002-09-20	2004-04-01	Merck & Co., Inc.	Derives d'octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide en tant que modulateurs selectifs de recepteur glucocorticoide
DE10246374A1 (de)	2002-10-04	2004-04-15	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
ATE392206T1 (de)	2002-10-11	2008-05-15	Pfizer	Indolderivate als beta-2 agonisten
EP1440966A1 (fr)	2003-01-10	2004-07-28	Pfizer Limited	Dérivés d'indole utilisables pour traiter des maladies
JP2006506373A (ja)	2002-10-22	2006-02-23	グラクソ　グループ　リミテッド	医薬アリールエタノールアミン化合物
KR20050065624A (ko)	2002-10-23	2005-06-29	그렌마크 파머수티칼스 엘티디.	염증성 및 알레르기 질환의 치료에 유용한 신규한트리사이클릭 화합물, 이의 제조 방법 및 이를 함유하는약제 조성물
BR0315720A (pt)	2002-10-28	2005-09-06	Glaxo Group Ltd	Composto, método para a profilaxia ou tratamento de uma condição clìnica em um mamìmefero, formulação farmacêutica, combinação, uso de um composto, processo para a preparação de um composto, e, intermediário
GB0225030D0 (en)	2002-10-28	2002-12-04	Glaxo Group Ltd	Medicinal compounds
GB0225287D0 (en)	2002-10-30	2002-12-11	Glaxo Group Ltd	Novel compounds
GB0225540D0 (en)	2002-11-01	2002-12-11	Glaxo Group Ltd	Medicinal compounds
GB0225535D0 (en)	2002-11-01	2002-12-11	Glaxo Group Ltd	Medicinal compounds
DE10253282A1 (de)	2002-11-15	2004-05-27	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
DE10253220A1 (de)	2002-11-15	2004-05-27	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE10253426B4 (de)	2002-11-15	2005-09-22	Elbion Ag	Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
DE10261874A1 (de)	2002-12-20	2004-07-08	Schering Ag	Nichtsteroidale Entzündungshemmer
EP1587818A4 (fr)	2003-01-21	2010-10-13	Merck Sharp & Dohme	Derives cortisol de 17-carbamoyloxy utilises en tant que modulateurs selectifs des recepteurs aux glucocorticoides
PE20040950A1 (es)	2003-02-14	2005-01-01	Theravance Inc	DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
US20050113423A1 (en)	2003-03-12	2005-05-26	Vangoor Frederick F.	Modulators of ATP-binding cassette transporters
EP1460064A1 (fr)	2003-03-14	2004-09-22	Pfizer Limited	Derivés de Indole-2-carboxamide comme beta-2 agonistes
US7696244B2 (en)	2003-05-16	2010-04-13	The Regents Of The University Of California	Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
GB0312832D0 (en)	2003-06-04	2003-07-09	Pfizer Ltd	2-amino-pyridine derivatives useful for the treatment of diseases
DE602004022819D1 (de)	2003-06-06	2009-10-08	Vertex Pharma	Von atp-bindende kassette transportern
EP1636269A2 (fr)	2003-06-10	2006-03-22	Ace Biosciences A/S	Polypeptides d'aspergillus extracellulaires
KR20060037450A (ko) *	2003-08-18	2006-05-03	패리온 사이언스 인코퍼레이티드	사이클릭 피라지노일구아니딘 나트륨 채널 차단제
EP1670475A4 (fr) *	2003-08-18	2009-04-15	Parion Sciences Inc	Bloqueurs du canal sodique a base de pyrazinoylguanidine alaphatique
CA2537841A1 (fr)	2003-09-06	2005-03-24	Vertex Pharmaceuticals Incorporated	Modulateurs de transporteurs a cassette de liaison a l'atp
KR20060121909A (ko)	2003-10-08	2006-11-29	버텍스 파마슈티칼스 인코포레이티드	사이클로알킬 또는 피라닐 그룹을 포함하는 ａｔｐ-결합카세트 수송자의 조절자
US7541466B2 (en)	2003-12-23	2009-06-02	Genzyme Corporation	Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
ES2631362T3 (es)	2004-01-30	2017-08-30	Vertex Pharmaceuticals Incorporated	Moduladores de transportadores de casete de unión a ATP
EP1765347A4 (fr)	2004-06-04	2008-10-01	Univ California	Composes intervenant dans l'acceleration du transport ionique par le cftr mutant, et utilisations desdits composes
JP5385605B2 (ja)	2005-03-11	2014-01-08	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｐ結合カセットトランスポーターのモジュレーター
KR20070114820A (ko)	2005-03-18	2007-12-04	더 리젠츠 오브 더 유니버시티 오브 캘리포니아	돌연변이-ｃｆｔｒ 처리를 보정하는데 활성을 가지는화합물 및 이것의 사용
WO2006127588A2 (fr)	2005-05-24	2006-11-30	Vertex Pharmaceuticals Incorporated	Modulateurs des transporteurs de cassette de liaison a l'atp
JP5143738B2 (ja)	2005-08-11	2013-02-13	バーテックスファーマシューティカルズインコーポレイテッド	嚢胞性線維症膜コンダクタンス制御因子の調節物質

2008
- 2008-05-05 MX MX2009012077A patent/MX2009012077A/es active IP Right Grant
- 2008-05-05 PE PE2008000782A patent/PE20090733A1/es not_active Application Discontinuation
- 2008-05-05 ES ES08759419T patent/ES2361595T3/es active Active
- 2008-05-05 BR BRPI0811562-1A2A patent/BRPI0811562A2/pt not_active IP Right Cessation
- 2008-05-05 AU AU2008248598A patent/AU2008248598B2/en not_active Ceased
- 2008-05-05 PL PL08759419T patent/PL2155721T3/pl unknown
- 2008-05-05 KR KR1020097025395A patent/KR20100005730A/ko not_active Abandoned
- 2008-05-05 CA CA002685546A patent/CA2685546A1/fr not_active Abandoned
- 2008-05-05 PT PT08759419T patent/PT2155721E/pt unknown
- 2008-05-05 JP JP2010506915A patent/JP5244904B2/ja not_active Expired - Fee Related
- 2008-05-05 EP EP11152559A patent/EP2332933A1/fr not_active Withdrawn
- 2008-05-05 EA EA200901489A patent/EA200901489A1/ru unknown
- 2008-05-05 US US12/451,152 patent/US8318935B2/en not_active Expired - Fee Related
- 2008-05-05 NZ NZ580737A patent/NZ580737A/en not_active IP Right Cessation
- 2008-05-05 WO PCT/EP2008/055497 patent/WO2008135557A1/fr active Application Filing
- 2008-05-05 AT AT08759419T patent/ATE499363T1/de active
- 2008-05-05 CN CN2008800226814A patent/CN101687851B/zh not_active Expired - Fee Related
- 2008-05-05 DE DE602008005140T patent/DE602008005140D1/de active Active
- 2008-05-05 EP EP08759419A patent/EP2155721B1/fr active Active
- 2008-05-06 CL CL2008001301A patent/CL2008001301A1/es unknown
- 2008-05-06 AR ARP080101913A patent/AR066458A1/es not_active Application Discontinuation
- 2008-05-06 TW TW097116687A patent/TWI351402B/zh not_active IP Right Cessation
2009
- 2009-10-26 ZA ZA200907491A patent/ZA200907491B/xx unknown
- 2009-10-29 IL IL201828A patent/IL201828A0/en unknown
- 2009-11-04 CR CR11091A patent/CR11091A/es unknown
- 2009-11-05 GT GT200900289A patent/GT200900289A/es unknown
- 2009-11-06 EC EC2009009718A patent/ECSP099718A/es unknown
- 2009-11-06 CO CO09125992A patent/CO6290667A2/es not_active Application Discontinuation
- 2009-11-06 TN TNP2009000469A patent/TN2009000469A1/fr unknown
- 2009-11-06 HN HN2009003214A patent/HN2009003214A/es unknown
- 2009-11-06 SV SV2009003406A patent/SV2009003406A/es active IP Right Grant
- 2009-11-30 MA MA32385A patent/MA31400B1/fr unknown

Also Published As

Publication number	Publication date
AR066458A1 (es)	2009-08-19
CL2008001301A1 (es)	2008-12-19
NZ580737A (en)	2012-03-30
PT2155721E (pt)	2011-05-09
KR20100005730A (ko)	2010-01-15
TWI351402B (en)	2011-11-01
PL2155721T3 (pl)	2011-07-29
HK1141285A1 (en)	2010-11-05
EA200901489A1 (ru)	2010-04-30
AU2008248598A1 (en)	2008-11-13
HN2009003214A (es)	2012-03-05
ECSP099718A (es)	2009-12-28
JP5244904B2 (ja)	2013-07-24
CR11091A (es)	2009-12-17
PE20090733A1 (es)	2009-07-17
TW200902517A (en)	2009-01-16
ZA200907491B (en)	2010-07-28
WO2008135557A1 (fr)	2008-11-13
US8318935B2 (en)	2012-11-27
ATE499363T1 (de)	2011-03-15
EP2332933A1 (fr)	2011-06-15
MX2009012077A (es)	2009-11-19
US20100105660A1 (en)	2010-04-29
EP2155721A1 (fr)	2010-02-24
EP2155721B1 (fr)	2011-02-23
GT200900289A (es)	2010-05-21
IL201828A0 (en)	2010-06-16
CO6290667A2 (es)	2011-06-20
CA2685546A1 (fr)	2008-11-13
SV2009003406A (es)	2010-01-12
DE602008005140D1 (de)	2011-04-07
AU2008248598B2 (en)	2011-11-17
BRPI0811562A2 (pt)	2014-12-09
MA31400B1 (fr)	2010-05-03
CN101687851B (zh)	2013-02-27
CN101687851A (zh)	2010-03-31
JP2010526118A (ja)	2010-07-29
ES2361595T3 (es)	2011-06-20

Publication	Publication Date	Title
TN2009000469A1 (en)	2011-03-31	Organic compounds
TW200745086A (en)	2007-12-16	Organic compounds
PH12022551574A1 (en)	2024-02-26	Egfr inhibitors
IN2012DN00999A (fr)	2015-04-10
MX2009012847A (es)	2009-12-08	Analogos dipeptidicos como inhibidores de factores de coagulacion.
MX2012010918A (es)	2013-01-18	Analogos para el tratamiento o prevencion de infecciones por flavivirus.
UA94833C2 (en)	2011-06-10	Substituted bicyclolactams
EA201170872A1 (ru)	2011-12-30	Ингибиторы протеинкиназы
MY146924A (en)	2012-10-15	Substituted imidazoheterocycles
MX2010013768A (es)	2011-03-03	Fosfatos ciclicos de nucleosidos.
MX2011011136A (es)	2011-11-18	Eteres diarilicos.
SG178952A1 (en)	2012-04-27	Chemical compounds
MX2009012418A (es)	2010-03-10	Derivados de quinazolin-oxima como inhibidores de hsp90.
MX2012007420A (es)	2012-07-23	Analogos para el tratamiento o prevencion de infecciones de flavivirus.
EA201170617A1 (ru)	2011-12-30	Пиразолиламинопиридины в качестве ингибиторов fak
ZA202201503B (en)	2023-11-29	Urea compound for antagonizing lpa1 receptor
MX2012002752A (es)	2012-04-19	Compuestos de heteroarilo como inhibidores de cinasa.
MX2009008540A (es)	2009-08-18	Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina.
MX2024000230A (es)	2024-04-01	Inhibidores de cdk2.
MX2011011776A (es)	2012-08-03	Nuevos profarmacos de triptolite.
MX2009012125A (es)	2010-02-18	Compuestos terapeuticos.
IN2012DN01273A (fr)	2015-05-15
MX2010008226A (es)	2010-10-25	Derivados de difluorobifenilamida para el tratamiento de hipertension ocular.
CR20240014A (es)	2024-05-07	Pirimidinil-pirazoles sustituidos como inhibidores de cdk2
GEP20156244B (en)	2015-02-10	New tertiary 8-hydroxyquinoline-7- carboxamide derivatives and usage thereof